The abstract is read at the publisher; the summary is JClub's.
Lecanemab infusions in early symptomatic Alzheimer’s disease patients are linked to significant, multidirectional changes in 34 of 130 plasma biomarkers, including partial normalization of p-tau217, MAPT, and GFAP.
- Why it matters: Anti-amyloid therapy slows decline, but it is unclear how plasma biomarkers tied to neurodegeneration shift over time and whether these patterns relate to amyloid PET status and cognition.
- What they did: In a longitudinal cohort at Washington University Memory Diagnostic Center, 197 lecanemab-started patients received 10 mg/kg IV every 2 weeks with blood draws about every 6 months for up to 2 years, analyzed with regression and mixed-effects models.
- The result: Biomarkers followed four trajectories—normalising, overcorrecting, opposite, and unchanged—suggesting lecanemab is associated with partial normalization of amyloid and tau alongside inflammatory and neurodegeneration-related changes, potentially enabling monitoring or prognosis pending validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.